

Alessandro Isidori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5135630/publications.pdf>

Version: 2024-02-01

145
papers

3,433
citations

159585

30
h-index

161849

54
g-index

149
all docs

149
docs citations

149
times ranked

4698
citing authors

#	ARTICLE	IF	CITATIONS
1	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	2.5	19
2	Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 371-379.	1.2	16
3	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	6.2	41
4	Editorial: The Biological Landscape of Immunotherapy in AML. <i>Frontiers in Oncology</i> , 2021, 11, 671252.	2.8	6
5	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
6	Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. <i>Frontiers in Oncology</i> , 2021, 11, 672287.	2.8	10
7	XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 818-820.	2.4	1
8	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	4.1	106
9	Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit. <i>Frontiers in Oncology</i> , 2020, 10, 1626.	2.8	3
10	Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience. <i>Frontiers in Oncology</i> , 2020, 10, 1689.	2.8	11
11	Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. <i>Frontiers in Oncology</i> , 2020, 10, 1439.	2.8	26
12	Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. <i>Blood Advances</i> , 2020, 4, 5040-5049.	5.2	4
13	Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 562558.	2.8	49
14	SARS-CoV-2 impact in a community-based hematological ward in an Italian Red Zone. <i>Annals of Hematology</i> , 2020, 99, 1677-1678.	1.8	1
15	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	1.7	15
16	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	1.8	17
17	BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 939.	2.8	83
18	The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1135.	2.8	30

#	ARTICLE	IF	CITATIONS
19	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1004.	2.8	23
20	Bendamustine prior to ASCT and renal toxicity: Much ado about nothing. <i>American Journal of Hematology</i> , 2019, 94, E104-E105.	4.1	2
21	Genomic profiling and predicting treatment response in acute myeloid leukemia. <i>Pharmacogenomics</i> , 2019, 20, 467-470.	1.3	9
22	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	1.7	3
23	High-dose Bendamustine-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 481-484.	2.4	10
24	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	1.8	10
25	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	1.4	0
26	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580.	1.8	32
27	Iron toxicity – Its effect on the bone marrow. <i>Blood Reviews</i> , 2018, 32, 473-479.	5.7	46
28	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	1.7	46
29	Efficacy and safety of ruxolitinib in intermediate- and high-risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	1.7	29
30	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. <i>Pharmacogenomics Journal</i> , 2018, 18, 444-449.	2.0	2
31	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.8	23
32	Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma. <i>International Journal of Hematologic Oncology</i> , 2018, 7, IJH01.	1.6	4
33	Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome. <i>Expert Review of Hematology</i> , 2018, 11, 455-461.	2.2	10
34	Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach. <i>Cancers</i> , 2018, 10, 211.	3.7	8
35	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	2.5	7
36	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	3.4	24

#	ARTICLE	IF	CITATIONS
37	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	1.4	11
38	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. <i>Blood</i> , 2018, 132, 1732-1732.	1.4	1
39	Single shot medium dose melphalan in resistant/relapsed myeloma: a bridge to target therapies?. <i>Trends in Transplantation</i> , 2018, 11, .	0.2	0
40	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	1.4	0
41	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	1.4	3
42	Enteric-coated mycophenolate sodium: a new option for GVHD prophylaxis?. <i>European Journal of Haematology</i> , 2017, 98, 320-321.	2.2	0
43	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. <i>Cancer Research</i> , 2017, 77, 3685-3699.	0.9	27
44	Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. <i>Leukemia Research</i> , 2017, 62, 77-83.	0.8	15
45	The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	1.8	14
46	PBSC mobilization in patients with autoimmune diseases: what's next. <i>European Journal of Haematology</i> , 2016, 97, 5-6.	2.2	2
47	Benda-BEAM High-Dose Therapy Prior to Auto-SCT is Effective in Resistant/Relapsed DLBCL. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S38.	2.0	0
48	AML therapy in the elderly: a time for a change. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 891-892.	2.4	3
49	Environmental nanoparticles are significantly over-expressed in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 50, 50-56.	0.8	16
50	Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. <i>Haematologica</i> , 2016, 101, e267-e268.	3.5	7
51	Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. <i>Leukemia and Lymphoma</i> , 2016, 57, 2499-2509.	1.3	36
52	Renewing the immunological approach to AML treatment: from novel pathways to innovative therapies. <i>Cancer Research Frontiers</i> , 2016, 2, 226-251.	0.2	2
53	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	1.8	24
54	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016, 128, 3078-3078.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. <i>Blood</i> , 2016, 128, 3951-3951.	1.4	0
56	Nanocarriers targeting cancer stem cells: how to help drugs to find their way home. <i>Nanomedicine</i> , 2015, 10, 1043-1046.	3.3	0
57	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
58	251 TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK. <i>Leukemia Research</i> , 2015, 39, S125.	0.8	0
59	Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL. <i>Blood</i> , 2015, 126, 1999-1999.	1.4	4
60	Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML. <i>Blood</i> , 2015, 126, 329-329.	1.4	2
61	Environmental Nanoparticles Are Significantly over-Expressed in Acute Myeloid Leukemia: a Novel Pathogenetic Cofactor?. <i>Blood</i> , 2015, 126, 4965-4965.	1.4	0
62	Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1675-1675.	1.4	0
63	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015, 126, 1582-1582.	1.4	0
64	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. <i>Blood</i> , 2015, 126, 4046-4046.	1.4	0
65	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015, 126, 1598-1598.	1.4	0
66	Advancement in high dose therapy and autologous stem cell rescue in lymphoma. <i>World Journal of Stem Cells</i> , 2015, 7, 1039-46.	2.8	6
67	The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. <i>Expert Review of Hematology</i> , 2014, 7, 807-818.	2.2	62
68	Conditioning regimens in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2014, 7, 465-479.	2.2	1
69	Nanomedicine strategies for hematological malignancies: what is next?. <i>Nanomedicine</i> , 2014, 9, 2415-2428.	3.3	13
70	Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. <i>Leukemia</i> , 2014, 28, 967-970.	7.2	13
71	Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 585-587.	2.4	26
72	Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1-3.	1.8	8

#	ARTICLE	IF	CITATIONS
73	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.8	30
74	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. <i>Blood</i> , 2014, 124, 3029-3031.	1.4	40
75	Clinical Experience with Liposomal Doxorubicin. <i>Frontiers in Nanobiomedical Research</i> , 2014, , 501-540.	0.1	0
76	Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. <i>Blood</i> , 2014, 124, 4532-4532.	1.4	0
77	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	2.7	36
78	High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future. <i>Expert Review of Hematology</i> , 2013, 6, 451-464.	2.2	17
79	Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2013, 6, 767-784.	2.2	23
80	Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2013, 129, 126-134.	1.4	5
81	Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 2134-2134.	1.4	1
82	Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 496-496.	1.4	0
83	The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome. <i>Blood</i> , 2013, 122, 2815-2815.	1.4	0
84	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012075.	1.3	6
85	UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012069.	1.3	6
86	Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. <i>Oncologist</i> , 2012, 17, 663-672.	3.7	52
87	Stem Cell Mobilization: An Overview. , 2012, , 51-60.		1
88	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. <i>Blood</i> , 2011, 118, 3273-3279.	1.4	356
89	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. <i>Blood</i> , 2011, 118, 3419-3425.	1.4	123
90	SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis. <i>PLoS ONE</i> , 2011, 6, e27560.	2.5	5

#	ARTICLE	IF	CITATIONS
91	The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). <i>Haematologica</i> , 2011, 96, e23-e24.	3.5	12
92	Doxorubicin variants for hematological malignancies. <i>Nanomedicine</i> , 2011, 6, 303-306.	3.3	11
93	The incidence of <i>Pneumocystis jirovecii</i> pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate <i>Pneumocystis jirovecii</i> pneumonia prophylaxis. <i>Leukemia and Lymphoma</i> , 2011, 52, 148-149.	1.3	5
94	Myeloid Sarcoma: The Clinician's Point of View. <i>Leukemia Research and Treatment</i> , 2011, 2011, 1-2.	2.0	1
95	LOW-DOSE LENALIDOMIDE COUPLED with LOW-DOSE Cytarabine INDUCES COMPLETE REMISSION of Elderly ACUTE Myeloid LEUKEMIA PATIENTS with Unfavorable Citogenetics: PRELIMINARY RESULTS of A PHASE II STUDY. <i>Blood</i> , 2011, 118, 3627-3627.	1.4	0
96	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. <i>American Journal of Hematology</i> , 2010, 85, 960-963.	4.1	13
97	editorial comment: Stem cell mobilization: the other side of the coin. <i>British Journal of Haematology</i> , 2010, 150, 663-664.	2.5	0
98	A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients. <i>Blood</i> , 2010, 116, 31-31.	1.4	10
99	Adoptive Immunotherapy with Haploidentical Kir Ligand-Mismatched Natural Killer Cells In Elderly High Risk Acute Myeloid Leukemia Patients: Biological and Clinical Results of A Pilot Study. <i>Blood</i> , 2010, 116, 4287-4287.	1.4	0
100	The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir. <i>Leukemia and Lymphoma</i> , 2009, 50, 294-296.	1.3	1
101	Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 357-363.	2.4	16
102	Efficacy of dasatinib in conjunction with α -interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. <i>Leukemia</i> , 2009, 23, 1687-1688.	7.2	13
103	Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study. <i>Blood</i> , 2009, 114, 1662-1662.	1.4	3
104	Identification of Novel Cryptic Chromosomal Abnormalities in Primary Myelofibrosis by Single-Nucleotide Polymorphism Oligonucleotide Microarray. <i>Blood</i> , 2009, 114, 1890-1890.	1.4	0
105	Long-term molecular complete remission with IFN- α in Ph+ adult acute lymphoid leukemia patients. <i>Leukemia</i> , 2008, 22, 1617-1618.	7.2	8
106	Stem cell mobilization and collection in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 932-939.	3.7	52
107	R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study. <i>Leukemia and Lymphoma</i> , 2008, 49, 1081-1086.	1.3	52
108	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 ⁺ into CD25 ⁺ T regulatory cells. <i>Blood</i> , 2007, 109, 2871-2877.	1.4	357

#	ARTICLE	IF	CITATIONS
109	Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1224-1232.	2.0	23
110	A diagnostic dilemma in stem cell transplantation for β^2 -Thalassemia major: progressive loss of take or pure red cell aplasia?. <i>International Journal of Hematology</i> , 2007, 86, 461-462.	1.6	0
111	Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. <i>Leukemia</i> , 2007, 21, 353-355.	7.2	99
112	Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. <i>British Journal of Haematology</i> , 2007, 136, 729-735.	2.5	32
113	R-COMP 21 (Prednisone, Cyclophosphamide, Vincristine, Myocetm and Rituximab) for Frail and Elderly Patients with Aggressive B-Cell Non-Hodgkin Lymphoma: A Pilot Study.. <i>Blood</i> , 2007, 110, 4442-4442.	1.4	0
114	An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. <i>Leukemia and Lymphoma</i> , 2006, 47, 2542-2546.	1.3	10
115	Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine. <i>Leukemia and Lymphoma</i> , 2006, 47, 1091-1102.	1.3	12
116	Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells. <i>Stem Cells</i> , 2006, 24, 454-461.	3.2	123
117	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. <i>Experimental Hematology</i> , 2005, 33, 1521-1530.	0.4	44
118	Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2005, 74, 277-281.	2.2	4
119	Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 477-479.	1.3	14
120	Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. <i>Haematologica</i> , 2005, 90, 139-41.	3.5	6
121	Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. <i>Haematologica</i> , 2005, 90, 225-31.	3.5	62
122	Low Dose Ara-C for Myelodysplastic Syndromes: is it Still a Current Therapy?. <i>Leukemia and Lymphoma</i> , 2004, 45, 1531-1538.	1.3	18
123	Generation of Dendritic Cells from Positively Selected CD14 ⁺ Monocytes for Anti-tumor Immunotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 1419-1428.	1.3	40
124	Dendritic Cell Differentiation. <i>Journal of Immunology</i> , 2004, 172, 3-4.	0.8	6
125	No Preferential Sensitivity of t(8;21) Acute Myeloid Leukemias to Cytosine Arabinoside in Vitro: Is Intensity of Therapy or High Dose Ara-C Crucial for Response?. <i>Leukemia and Lymphoma</i> , 2004, 45, 1361-1364.	1.3	3
126	Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1791-1795.	1.3	67

#	ARTICLE	IF	CITATIONS
127	Efficacy and Toxicity of FLAI vs ICE for Induction Treatment of Newly Diagnosed AML Patients, Younger Than 60 Years.. Blood, 2004, 104, 878-878.	1.4	0
128	Purification of Allogeneic Idiotype-Specific T Lymphocytes According to IFN- β Production for Adoptive Immunotherapy in Multiple Myeloma Patients.. Blood, 2004, 104, 2119-2119.	1.4	0
129	Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment.. Blood, 2004, 104, 1816-1816.	1.4	6
130	Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBF β /MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. Leukemia, 2003, 17, 650-651.	7.2	8
131	Microdose β -interferon shows clinical and antiangiogenic effect in extramedullary myeloid tumor: a case report. Leukemia, 2003, 17, 986-987.	7.2	4
132	Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. Leukemia, 2003, 17, 1669-1670.	7.2	10
133	Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood, 2003, 102, 1595-1600.	1.4	33
134	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 2002, 99, 443-449.	1.4	133
135	Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia, 2002, 16, 1609-1614.	7.2	54
136	Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. Leukemia, 2002, 16, 1880-1881.	7.2	12
137	Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia. Leukemia, 2002, 16, 2159-2160.	7.2	12
138	Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia, 2001, 15, 764-771.	7.2	35
139	The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia - analysis of 848 patients. Leukemia, 2001, 15, 903-909.	7.2	65
140	Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. Bone Marrow Transplantation, 2001, 27, 829-835.	2.4	7
141	Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. British Journal of Haematology, 2000, 109, 722-728.	2.5	30
142	All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. European Journal of Haematology, 2000, 64, 139-144.	2.2	23
143	Chemotherapy of Secondary Leukemias. Leukemia and Lymphoma, 2000, 37, 543-549.	1.3	8
144	All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. European Journal of Haematology, 1999, 63, 149-153.	2.2	14

#	ARTICLE	IF	CITATIONS
145	ENL YEATS domain: targeting the acute myeloid leukemia epigenome. Biotarget, 0, 2, 12-12.	0.5	1